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Need for new biomarkers in rheumatic disease
Large epidemiology studies have demonstrated that cardiovascular events are a leading cause of morbidity and mortality in rheumatic diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (1) (2) (3) . This enhanced risk of premature atherosclerosis is independent of traditional risk factors and is partly attributable to persistent systemic inflammation, atherogenic therapies such as glucocorticoids, and a procoagulant environment (4) . Autoimmune rheumatic diseases such as SLE, RA and systemic sclerosis (SSc) have presented challenges in the clinic because of their unclear disease aetiology and their unpredictable disease progression, demanding a need for improved and more accurate assessment of disease activity, prognosis and co-morbidity, with a view to ultimately allow a more personalised approach to therapy.
There are several reports linking elevated endothelial microparticles (EMPs) with the immunopathogenesis of rheumatic diseases, via their potential role in the regulation of inflammation, thrombosis and angiogenesis (5) . EMPs are of particular interest in SLE and related connective tissue diseases (CTDs), given the importance of the endothelium in both inflammatory disease manifestations and the role of endothelial dysfunction in the early stages of atherosclerosis. Endothelial cell dysfunction (ECD), characterised by a shift of the actions of the endothelium toward reduced vasodilation, a proinflammatory state and enhanced prothrombotic properties, is emerging as the common denominator for diverse and highly prevalent cardiovascular diseases. Mechanisms that participate in the reduced vasodilatory responses in endothelial dysfunction include reduced nitric oxide generation and oxidative excess. Upregulation of adhesion molecules, generation of chemokines such as macrophage chemoattractant peptide-1, and production of plasminogen activator inhibitor-1 participate in the inflammatory response and contribute to a prothrombic state.
Detachment and apoptosis of endothelial cells are associated phenomena (6).
We and others, have associated elevated EMPs with cardiovascular diseases and a correlation with high atherosclerotic plaque grade (7) (8) (9) (10) . Furthermore, EMP composition may reflect as yet unidentified important biological functions in disease pathogenesis and vascular dysfunction, and contribute to the increased cardiovascular risk present in a number of inflammatory diseases. Our own studies have shown the number of circulating EMPs correlates with the inflammatory status of SLE, and inversely relates to endothelial function in this patient group, raising the interest in the potential use of EMPs as a biomarker for the increased cardiovascular risk in SLE (11) .
Characteristics of endothelial microparticles
MPs, also referred to as microvesicles (MVs), may originate from different vascular cell types including platelets, monocytes, endothelial cells, red blood cells, and granulocytes. In health, it has been reported than >80% of circulating MPs express membrane antigens that suggest a platelet origin (12) . MPs form when the asymmetrical distribution of lipids between the inner and outer leaflets of a plasma membrane is lost (13) . Under resting conditions, phosphatidylserine (PS) is located almost exclusively in the inner monolayer (14) .
When cells undergo activation or apoptosis, PS translocation to the outer leaflet is the initial event that will ultimately lead to the shedding of MPs that are therefore regarded as markers of cell stress (13 suggesting that these microparticles represent a surrogate marker of ECD. To date it has been impossible to identify the specific vascular bed from which EMPs are derived due to a lack of specific surface markers; however, the total EMP population is thought to reflect the overall health of the endothelium. It should be noted that low levels of EMPs are also detected in healthy controls (10, 19, 21) , suggesting that EMPs may also have a potential role in the homeostatic regulation of the healthy vascular endothelium.
Endothelial microparticle function
It is increasingly recognised that EMP function is more nuanced than previously considered, and the micro-environment stimulating EMP release appears to be a key contributor to the functional properties exhibited by EMPs (22 (24, 25) .
Proteomic analysis of cell-culture derived EMPs has shown that one third of the proteins found on EMPs are specific to the stimulus initiating their release, not only demonstrating the plasticity of these vesicles but also revealing the complexity of the mechanisms governing their formation (26) . Taken together, these findings suggest that there are distinct mechanisms for the formation of EMPs in apoptotic and activated cells (27) , with several studies suggesting that these types of EMPs have different functions in vascular diseases (28, 29) . Thus, we suggest EMPs may provide a measure of the health of the underlying endothelial. However, their utility as biomarkers of disease must also take into account potential differences between the healthy and disease states.
Pathogenic effects of endothelial microparticles on the endothelium
A number of studies have shown that TNF-α, a key cytokine involved in the pathogenesis of a number of rheumatic diseases, activates endothelial cells and induces release of EMPs (24) (25) (26) . EMPs produced under these conditions have been used in a number of functional studies. High levels of the surface antigens E-selectin, intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) have been detected on EMPs derived from activated endothelial cells and can mediate adhesion of monocytes to endothelial cells in vitro (30) . These data suggest that EMPs may be both a consequence and a cause of the inflammatory response.
EMPs have also been shown to play a role in thrombosis (31) . Phosphotidylserine (PS) is expressed on released EMPs, which confers a procoagulant property to EMPs, due to the ability of PS to bind and activate coagulation factors (32) . It has been reported that EMPs also contain tissue factor (TF), which can initiate the extrinsic coagulation pathway (24, 33) .
This thrombogenic activity of EMPs has been confirmed by the demonstration that EMPtriggered TF-dependent release, promotes thrombin formation in vitro and thrombus formation in vivo (34) .
EMPs impair vasorelaxation and bioavailability of endothelial-derived nitric oxide (NO)
production by aortic cells in healthy animal models in a concentration-dependent manner, suggesting that circulating EMPs may directly affect endothelial-dependent vasodilatation and thus, not only act as a marker for ECD, but also potentially aggravate pre-existing ECD (35) .
EMPs isolated from end-stage renal disease patients with cardiovascular disease have been shown to impair the release of nitric oxide from vascular cells and platelet-derived MPs can act as a source for thromboxane A2, which increases vascular contraction (36) . EMPs may also be involved in cross-talk with the smooth muscle layer. Recent work has shown that EMPs produced under inflammatory conditions were able to induce vascular calcification in smooth muscle cells, thus contributing to vessel stiffness (37) .
Restorative effects of endothelial microparticles
In contrast to their proposed role in ECD, we and others have detected a functional endothelial nitric oxide synthase (eNOS) in EMPs (38) . In our in vitro study, EMPs were able products that are vasculoprotective in acute inflammatory conditions, whilst also having the capacity to, not only perpetuate further vascular dysfunction in chronic disease, but also act as surrogates of vascular dysfunction (11, (44) (45) (46) . How this translates to the effects observed in patients remains to be determined.
The role of endothelial microparticles in rheumatic diseases
Rheumatoid arthritis
It has been reported in a range of studies in RA patients that EMP (and total MP) numbers are increased in comparison to healthy controls (HC), as well as being associated with disease specific features such as disease activity (47) . MPs isolated from RA patients demonstrate potent ability to activate the endothelium in vitro, whilst having a deleterious effect on endothelial cell function, thus supporting their role as a marker of vascular damage in disease (47) . Similarly, our own group has previously reported that at a cellular level, a clinically available TNF-α inhibitor (Certolizumab) prevents TNF-α induced activation of the NF-κB pathway and prevents MP production by activated endothelial cells, suggesting a potential novel mechanism by which anti -TNF therapy may improve cardiovascular outcomes in inflammatory arthritis patients (25) .
Systemic Lupus Erythematosus
EMPs have also been shown to be elevated in SLE, in both active and low disease activity states (11, 48) . Anti-endothelial cell antibodies (AECAs) do not seem to be the main cause of endothelial dysfunction in this population, with EMPs instead being released from the endothelium of activated and apoptotic cells (48) . In active SLE, EMP numbers are In support of this, EMP levels were also associated with Lupus Anticoagulant (LA). In contrast however, Jy et al described elevated EMP counts in individuals with aPL, although this increase was independent of a history of thrombosis; PMP counts in contrast were increased only in patients with aPL and a thrombotic event (61) . These findings suggest that aPL might cause chronic endothelial cell activation or injury, leading to the enhanced shedding of EMPs. Interestingly, aPL-positivity in SLE has also been associated with the presence of carotid plaque, supporting their role in chronic endothelial injury (62) . In contrast, only certain aPL specificities might cause the activation of platelets and the release of PMPs, which increase the risk for thrombosis. Therefore, the EMP/PMP ratio could be key to successful stratification within this patient group.
Vasculitides
Increased numbers of EMPs during the acute phase of vasculitides have also been reported, with patients in remission displaying normal levels (63) . Barriers to the use of endothelial microparticles as biomarkers.
EMPs are identified and enumerated via flow cytometry using a panel of markers; most commonly Annexin V + to indicate PS-positivity. Endothelial cell markers used vary between groups and the combination of CD31 + /CD42b -is widely used (9, 68) but remains an imperfect choice (44, 64) . Platelet cell adhesion molecule (PECAM-1 or CD31) is present on both endothelial and platelet-derived MPs (PMPs), therefore, CD42-negativity is used to exclude PMPs. Other combinations used to detect EMPs, include CD144 (VE-cadherin), CD54
(intracellular adhesion molecule-1 (ICAM)), and CD62e (E-selectin) (44, 64) . Again, these markers remain problematic as they only detect a sub-population of EMPs (for example, from activated endothelial cells only) and therefore may only be present at lower levels (23, 69) . The process of identifying and quantifying EMPs involves several distinct stages -blood collection, centrifugation, antibody detection of cell surface antigens, and flow cytometryand there is significant variation at all stages, and there is a growing consensus that for accurate assessment of microparticles, a firm set of guidelines is needed (70, 71) . Previous reviews have extensively highlighted the difficulties, methods and potential characteristic markers that may be used in this process (72) . It may be that additional methods should be employed to enable accurate phenotyping, sizing, and enumeration of the wide range of MPs generated from different vascular beds and different cell types, in order to fully understand the biology of these microparticles. This may also remove variation between sample handling between different laboratories. These additional methods may include electron and atomic force microscopy, together with a full RNA, lipid, and protein profiling exercise.
Conclusion: Are endothelial microparticles friends or foes?
In conclusion, EMPs can be considered as complex structures displaying a large repertoire of endothelial-derived molecules and biological functions, depending on their composition.
When the data are taken together, the involvement of EMP in vascular homeostasis appears to be more complex than initially thought. EMPs can play a major role in inflammation, thrombosis, angiogenesis and repair as summarised in Figure 1 
